Monopar Therapeutics Inc. (MNPR)
37.82
-0.54 (-1.41%)
At close: Apr 16, 2025, 3:59 PM
39.33
3.99%
After-hours: Apr 16, 2025, 05:27 PM EDT
-1.41% (1D)
| Bid | 35.5 |
| Market Cap | 231.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.32B |
| EPS (ttm) | -4.11 |
| PE Ratio (ttm) | -9.2 |
| Forward PE | -18.34 |
| Analyst | Buy |
| Ask | 41 |
| Volume | 17,767 |
| Avg. Volume (20D) | 47,714 |
| Open | 38.20 |
| Previous Close | 38.36 |
| Day's Range | 35.84 - 37.99 |
| 52-Week Range | 1.72 - 54.30 |
| Beta | 1.02 |
About MNPR
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubic...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 19, 2019
Employees 14
Stock Exchange NASDAQ
Ticker Symbol MNPR
Website https://www.monopartx.com
Analyst Forecast
According to 4 analyst ratings, the average rating for MNPR stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 32.21% from the latest price.
Stock Forecasts4 months ago
+2.38%
Monopar Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
5 months ago
+5.32%
Monopar Therapeutics shares are trading lower after the company announced a proposed public offering of common stock.
